SG11201606316XA - Methods of treating alzheimer's disease - Google Patents

Methods of treating alzheimer's disease

Info

Publication number
SG11201606316XA
SG11201606316XA SG11201606316XA SG11201606316XA SG11201606316XA SG 11201606316X A SG11201606316X A SG 11201606316XA SG 11201606316X A SG11201606316X A SG 11201606316XA SG 11201606316X A SG11201606316X A SG 11201606316XA SG 11201606316X A SG11201606316X A SG 11201606316XA
Authority
SG
Singapore
Prior art keywords
disease
methods
treating alzheimer
alzheimer
treating
Prior art date
Application number
SG11201606316XA
Inventor
William Cho
Michel Friesenhahn
Robert Paul
Michael Ward
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52684643&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201606316X(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of SG11201606316XA publication Critical patent/SG11201606316XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
SG11201606316XA 2014-02-08 2015-02-06 Methods of treating alzheimer's disease SG11201606316XA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461937472P 2014-02-08 2014-02-08
US201461971479P 2014-03-27 2014-03-27
US201462010259P 2014-06-10 2014-06-10
US201462081992P 2014-11-19 2014-11-19
PCT/US2015/014758 WO2015120233A1 (en) 2014-02-08 2015-02-06 Methods of treating alzheimer's disease

Publications (1)

Publication Number Publication Date
SG11201606316XA true SG11201606316XA (en) 2016-08-30

Family

ID=52684643

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201913637RA SG10201913637RA (en) 2014-02-08 2015-02-06 Methods of treating alzheimer's disease
SG11201606316XA SG11201606316XA (en) 2014-02-08 2015-02-06 Methods of treating alzheimer's disease

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201913637RA SG10201913637RA (en) 2014-02-08 2015-02-06 Methods of treating alzheimer's disease

Country Status (19)

Country Link
US (3) US20150246963A1 (en)
EP (2) EP3718563A1 (en)
JP (4) JP6685912B2 (en)
KR (3) KR20160111039A (en)
CN (1) CN106163548A (en)
AU (1) AU2015214058B2 (en)
BR (1) BR112016018170A2 (en)
CA (1) CA2938466C (en)
CL (2) CL2016001979A1 (en)
HK (1) HK1231401A1 (en)
IL (1) IL246999B (en)
MX (1) MX2016010173A (en)
MY (1) MY179105A (en)
NZ (1) NZ723884A (en)
RU (1) RU2724190C2 (en)
SG (2) SG10201913637RA (en)
TW (1) TWI705824B (en)
WO (1) WO2015120233A1 (en)
ZA (1) ZA201605341B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2941415A1 (en) * 2014-03-21 2015-09-24 Alzheon, Inc. Methods for treating neurological disorders
MA41115A (en) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh ALZHEIMER'S DISEASE TREATMENT PROCESS
GB2541003A (en) * 2015-08-05 2017-02-08 Kran Life Sciences Llp Neurodegenerative disorders
CN116712423A (en) * 2015-09-10 2023-09-08 阿尔泽恩股份有限公司 Methods of treating neurodegenerative disorders in a particular patient population
BR112018008407A2 (en) 2015-10-28 2018-11-27 Univ Pennsylvania intrathecal administration of adeno-associated viral vectors for gene therapy
CN108602883A (en) * 2016-01-20 2018-09-28 基因泰克公司 High-dose therapy for Alzheimer's disease
AU2017276656A1 (en) * 2016-06-07 2018-12-13 Biogen International Neuroscience Gmbh Methods for treating alzheimer's disease
AU2017301736A1 (en) * 2016-07-29 2019-03-14 Biogen Chesapeake Llc Methods of treating or preventing amyloid related imaging abnormalities associated with alzheimer's disease treatment
IT201600118499A1 (en) * 2016-11-25 2018-05-25 Giacomo Koch Use of dopaminergic agonists for the prevention of early stage Alzheimer's disease progression.
WO2018207154A1 (en) * 2017-05-12 2018-11-15 The Hong Kong University Of Science And Technology Heterocyclic compounds as epha4 inhibitors
IL272773B1 (en) 2017-08-22 2024-02-01 Biogen Ma Inc Pharmaceutical compositions containing anti-beta amyloid antibodies
WO2019182319A1 (en) * 2018-03-20 2019-09-26 (주)인벤티지랩 Method for preparing pharmaceutical composition for preventing or treating cognitive disorder-associated diseases, and pharmaceutical composition for preventing or treating cognitive disorder-associated diseases, prepared by preparation method
KR102224917B1 (en) 2018-03-20 2021-03-09 (주)인벤티지랩 Production methods of preventing or treating cognitive impairment-related disease and preventing or treating cognitive impairment-related disease producing thereto
CN112601513B (en) * 2018-04-05 2023-12-22 普莱克斯医药公司 Medicine for treating eye diseases
WO2023004386A1 (en) 2021-07-22 2023-01-26 Genentech, Inc. Brain targeting compositions and methods of use thereof

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
JP2919890B2 (en) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル Single domain ligand, receptor consisting of the ligand, method for producing the same, and use of the ligand and the receptor
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
DE122004000008I1 (en) 1991-06-14 2005-06-09 Genentech Inc Humanized heregulin antibody.
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
JP3951062B2 (en) 1991-09-19 2007-08-01 ジェネンテック・インコーポレーテッド Expression of antibody fragments with cysteine present at least as a free thiol in E. coli for the production of bifunctional F (ab ') 2 antibodies
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ATE295420T1 (en) 1992-02-06 2005-05-15 Chiron Corp MARKER FOR CANCER AND BIOSYNTHETIC BINDING PROTEIN FOR IT
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
EP0994903B1 (en) 1997-06-24 2005-05-25 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
EP1028751B1 (en) 1997-10-31 2008-12-31 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
PT1034298E (en) 1997-12-05 2012-02-03 Scripps Research Inst Humanization of murine antibody
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
EP2261229A3 (en) 1998-04-20 2011-03-23 GlycArt Biotechnology AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
NZ539776A (en) 1999-01-15 2006-12-22 Genentech Inc Polypeptide variants with altered effector function
EP2270148A3 (en) 1999-04-09 2011-06-08 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CA2385347C (en) 1999-10-04 2009-12-15 Medicago Inc. Method for regulating transcription of foreign genes
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
AU7950400A (en) 1999-10-19 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Process for producing polypeptide
WO2001044463A1 (en) 1999-12-15 2001-06-21 Genentech, Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
ES2637801T3 (en) 2000-04-11 2017-10-17 Genentech, Inc. Multivalent antibodies and uses thereof
ES2639222T5 (en) 2000-10-06 2023-11-24 Kyowa Kirin Co Ltd Cells that produce antibody compositions
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
ES2295228T3 (en) 2000-11-30 2008-04-16 Medarex, Inc. TRANSGROMIC TRANSCROMOSOMIC ROLLERS FOR THE PREPARATION OF HUMAN ANTIBODIES.
CN1555411A (en) 2001-08-03 2004-12-15 ���迨�����＼���ɷݹ�˾ Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
DE60336548D1 (en) 2002-04-09 2011-05-12 Kyowa Hakko Kirin Co Ltd CELL WITH REDUCED OR DELETED ACTIVITY OF A PROTEIN INVOLVED IN GDP FUCOSET TRANSPORT
WO2003084569A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Drug containing antibody composition
CA2481658A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to fcy receptor iiia
WO2003084570A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
JPWO2003085118A1 (en) 2002-04-09 2005-08-11 協和醗酵工業株式会社 Method for producing antibody composition
PL373256A1 (en) 2002-04-09 2005-08-22 Kyowa Hakko Kogyo Co, Ltd. Cells with modified genome
AU2003239966B9 (en) 2002-06-03 2010-08-26 Genentech, Inc. Synthetic antibody phage libraries
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1944320A1 (en) 2002-12-16 2008-07-16 Genentech, Inc. Immunoglobulin variants and uses thereof
WO2004065416A2 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
EP1688439A4 (en) 2003-10-08 2007-12-19 Kyowa Hakko Kogyo Kk Fused protein composition
JPWO2005035778A1 (en) 2003-10-09 2006-12-21 協和醗酵工業株式会社 Method for producing antibody composition using RNA that suppresses function of α1,6-fucosyltransferase
PL1692182T3 (en) 2003-11-05 2010-09-30 Roche Glycart Ag Cd20 antibodies with increased fc receptor binding affinity and effector function
JPWO2005053742A1 (en) 2003-12-04 2007-06-28 協和醗酵工業株式会社 Medicament containing antibody composition
RU2386638C2 (en) 2004-03-31 2010-04-20 Дженентек, Инк. Humanised anti-tgf-beta-antibody
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
DK1737891T3 (en) 2004-04-13 2013-03-25 Hoffmann La Roche ANTI-P-selectin ANTIBODIES
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
CN101065151B (en) 2004-09-23 2014-12-10 健泰科生物技术公司 Cysteine engineered antibodies and conjugates
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
US7625560B2 (en) * 2004-12-15 2009-12-01 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
WO2007056441A2 (en) 2005-11-07 2007-05-18 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
KR20180058863A (en) * 2005-11-30 2018-06-01 애브비 인코포레이티드 Monoclonal antibodies against amyloid beta protein and uses thereof
US20070237764A1 (en) 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
KR101591223B1 (en) * 2005-12-12 2016-02-04 에이씨 이뮨 에스.에이. A beta 1-42 specific monoclonal antibodies with therapeutic properties
AU2007249408A1 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
PL2046833T3 (en) * 2006-07-14 2014-01-31 Ac Immune Sa Humanized antibody against amyloid beta
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CN100592373C (en) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 Liquid crystal panel drive device and its drive method
JO3076B1 (en) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
SI2235064T1 (en) 2008-01-07 2016-04-29 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
AU2011240556B2 (en) * 2010-04-13 2012-06-21 Baxalta GmbH Use of ventricular enlargement rate in intravenous immunoglobulin treatment of Alzheimer's disease
MY164579A (en) * 2010-07-30 2018-01-15 Ac Immune Sa Safe and functional humanized antibodies
JP2014001232A (en) * 2013-09-02 2014-01-09 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic disease

Also Published As

Publication number Publication date
CL2016001979A1 (en) 2017-02-10
EP3102231A1 (en) 2016-12-14
JP2020073507A (en) 2020-05-14
ZA201605341B (en) 2021-01-27
JP2022058369A (en) 2022-04-12
CL2017002781A1 (en) 2018-04-13
SG10201913637RA (en) 2020-03-30
HK1231401A1 (en) 2017-12-22
BR112016018170A2 (en) 2018-02-20
RU2016136081A (en) 2018-03-13
JP6685912B2 (en) 2020-04-22
MY179105A (en) 2020-10-28
CA2938466A1 (en) 2015-08-13
KR20230056800A (en) 2023-04-27
CN106163548A (en) 2016-11-23
TW201613636A (en) 2016-04-16
MX2016010173A (en) 2016-10-13
EP3102231B1 (en) 2019-09-11
IL246999A0 (en) 2016-09-29
JP2017511793A (en) 2017-04-27
TWI705824B (en) 2020-10-01
KR20210121288A (en) 2021-10-07
RU2724190C2 (en) 2020-06-23
AU2015214058B2 (en) 2020-07-09
WO2015120233A1 (en) 2015-08-13
US20220195020A1 (en) 2022-06-23
KR20160111039A (en) 2016-09-23
EP3718563A1 (en) 2020-10-07
NZ723884A (en) 2023-02-24
JP2024037893A (en) 2024-03-19
RU2016136081A3 (en) 2018-09-28
IL246999B (en) 2020-09-30
US20200399352A1 (en) 2020-12-24
AU2015214058A1 (en) 2016-08-11
US20150246963A1 (en) 2015-09-03
CA2938466C (en) 2021-11-02

Similar Documents

Publication Publication Date Title
IL285722A (en) Methods for treating alzheimer's disease
ZA201605341B (en) Methods of treating alzheimer's disease
IL247085A0 (en) Methods of treating alzheimer's disease
IL276315A (en) Donepezil compositions and method of treating alzheimer's disease
SG11201701723XA (en) Methods of treating liver disease
GB201701673D0 (en) Methods of well treatment
IL263433A (en) Methods for treating alzheimer's disease
HK1245127A1 (en) Methods and compositions for treating brain diseases
HK1243709A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer's disease
EP3137097C0 (en) Treatment and prevention of alzheimer's disease (ad)
HK1243937A1 (en) Methods of treating diseases
PL3137094T3 (en) Treatment and prevention of alzheimer's disease (ad)
PL3137093T3 (en) Treatment and prevention of alzheimer's disease (ad)
HK1246271A1 (en) Method for the synthesis of hydroxy-triglycerides and uses thereof for the prevention and treatment of diseases
HK1245081A1 (en) Methods for treating alzheimer's disease
GB201511453D0 (en) Treatment of alzheimer's disease
GB201621398D0 (en) Treatment of emt-associated disease
GB201504144D0 (en) Treatment of Parkinson's disease
GB201414038D0 (en) Alzheimer's disease
GB201504413D0 (en) Treatment of disease